Adjuvant Nutrition for Critically III Trauma Patients

危重 III 级创伤患者的辅助营养

• 批准号: 6582697
• 负责人: John A Rathmacher
• 金额: $ 10万
• 依托单位: METABOLIC TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-02-01 至 2004-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6582697
• 关键词: arginine; atrophy; carboxylate; clinical research; critical care; dietary supplements; glutamine; human subject; human therapy evaluation; malnutrition; nitrogen metabolism; nutrition related tag; outcomes research; parenteral feedings; patient oriented research; proteolysis; sarcopenia; trauma

DESCRIPTION (provided by applicant): Of the four million cases of trauma cases each year that will require hospitalization, 200,000 will be classified as severe trauma. During the hospital stay, malnutrition is a major complication in about 50% of the patient population. The result is muscle wasting which is a major risk factor for increased morbidity and mortality. In the study proposal presented we postulate that supplementation with Beta-hydroxy-Beta-methylbutyrate (HMB), arginine and glutamine (HMB/Arg/Gln) to these severely traumatized patients can stem the loss of muscle tissue and whole body nitrogen and in turn decrease morbidity and mortality. This hypothesis is based on two recent studies showing the same nutritional mixture of HMB/Arg/Gln can reverse the muscle wasting associated with AIDS and Cancer. The hypermetabolic state seen in AIDS and cancer have a similar multilifactorial etiology seen in trauma. There is an increase in the mobilization of fat and muscle, increased or normal metabolic rate, increased protein breakdown, and an increased or normal glucose turnover. In addition, HMB alone has been shown to reduce nitrogen loss, decrease muscle proteolysis and muscle damage within the first 48 hours to three week after initiating supplementation. Male and female patients (n=100) will be recruited at the time of admittance to the Trauma ICU with an ISS of greater than 18 Patients who meet the inclusion/exclusion will be randomized to receive either 1) standard tube feed plus HMB/Arg/Gln, standard tube feed plus HMB alone, or standard tube feed (control) in a blinded fashion. Clinical outcomes measures will be assessed through out the hospital stay and on a outpatient basis on week 4 and week 12. Muscle proteolysis and nitrogen economy will be evaluated on daily basis while in the hospital and after 4 weeks on an out patient basis. If as expected, Phase I results confirm the effectiveness of the nutrient mixture in trauma patients. Expanded multicenter studies will be proposed in Phase II.

描述(申请人提供)：在每年需要住院的400万例创伤病例中，20万例将被归类为严重创伤。在住院期间，营养不良是约50%患者的主要并发症。其结果是肌肉萎缩，这是增加发病率和死亡率的主要风险因素。在我们提出的研究建议中，我们假设对这些严重创伤患者补充β-羟基-β-甲基丁酸酯(HMB)、精氨酸和谷氨酰胺(HMB/Arg/Gln)可以阻止肌肉组织和全身氮的丢失，从而降低发病率和死亡率。这一假设是基于最近的两项研究，这些研究表明，相同的HMB/Arg/Gln营养混合物可以逆转与艾滋病和癌症相关的肌肉萎缩。艾滋病和癌症的高代谢状态与创伤的多因素病因相似。脂肪和肌肉的动员增加，代谢率增加或正常，蛋白质分解增加，葡萄糖周转增加或正常。此外，单独的HMB已被证明可以在开始补充后的48小时到三周内减少氮损失，减少肌肉蛋白分解和肌肉损伤。 男性和女性患者(n=100)将在入院时被招募到创伤ICU，ISS大于18的患者将被随机分为1)标准管喂加HMB/Arg/Gln，标准管喂加HMB，或标准管喂(对照)盲法。临床结果评估将在第4周和第12周的出院和门诊基础上进行。肌肉蛋白分解和氮经济性将在住院期间和4周后的门诊基础上进行每日评估。 如果如预期的那样，I期结果证实了营养混合物在创伤患者中的有效性。第二阶段将提出扩大多中心研究的建议。